Actively Recruiting

Age: 50Years - 85Years
All Genders
ID07428447

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

Led by CND Life Sciences · Updated on 2026-02-23

300

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

Sponsors

C

CND Life Sciences

Lead Sponsor

N

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Essential tremor (ET) affects over 6 million Americans and about 5% of adults over age 60. People with ET have a significantly higher chance of developing Parkinson's disease (PD) compared to others their age, with about 1% developing PD each year. Some ET patients show Lewy body pathology after death, indicating that a portion may be in early stages of PD. Current screening tests for early PD are either not sensitive enough, costly, or invasive. This study looks at the Syn-One Test, which uses a small skin biopsy to detect phosphorylated alpha-synuclein (P-SYN), a marker linked to PD. Participants diagnosed with ET or ET-Plus will be observed to find out if they have P-SYN in their skin and to predict who may develop PD over time. The study includes adults aged 50 to 85 years and follows them from the start for up to 24 months. Participants will be divided into groups based on their diagnosis of ET or ET-Plus. During the study, researchers will measure the amount of P-SYN in skin samples at the start, at 12 months, and again at 24 months. They will also track if and when participants develop PD symptoms. Participants must complete all study procedures and give informed consent. Safety factors like wound healing and anesthesia allergies are considered to protect participants.

CONDITIONS

Brief Title

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

Who Can Participate

Age: 50Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 50 to 85 years old
  • Diagnosis of Essential Tremor as defined by the 2018 MDS Task force: isolated bilateral upper limb action tremor for at least 3 years, with or without tremor in other locations, and no other neurological signs
  • Diagnosis of Essential Tremor Plus as defined by the 2018 MDS Task force: ET characteristics plus additional mild neurological signs of uncertain significance
  • Willing to participate in all study procedures
  • Able and willing to provide written informed consent
Not Eligible

You will not qualify if you...

  • Under age 50 or over age 85
  • Severe peripheral vascular disease
  • Clinically active coronary artery or cerebrovascular disease
  • Currently on anticoagulant or dual anti-platelet therapy
  • Alcoholism
  • Allergic reaction to local anesthesia
  • History or risk of impaired wound healing, scarring, or keloid formation
  • ET or ET-Plus likely secondary to brain injury or vascular compromise
  • History of other neurodegenerative disorders or neurological co-pathology
  • Abnormal DaTscan
  • Currently receiving carbidopa-levodopa treatment for Parkinson's disease
  • Isolated focal tremors (head, voice)
  • Task-specific tremor (e.g., primary writing tremor)
  • Position-specific tremors that do not meet ET diagnostic criteria
  • Sudden onset and step-wise deterioration

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Baseline to Month 12

Participants undergo assessments including skin biopsy to measure phosphorylated alpha-synuclein and evaluate neurological signs.

Visits at Baseline and Month 12

Long-term Monitoring

Duration - Month 12 to Month 24

Participants are observed over time to monitor progression from Essential Tremor to Parkinson's Disease.

Visit at Month 24

Trial Site Locations

Total: 1 location

1

CND Clinical Research Center

Scottsdale, Arizona, United States, 85258

Actively Recruiting

Loading map...

Research Team

J

Jeannie Director of Clinical Research

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

24-month Open-label Study to Evaluate Safety, Tolerability, ...

Parkinson Disease

Actively Recruiting

1 location

3-D Tractography Focused Ultrasound Ablation for Essential T...

Essential Tremor

Actively Recruiting

1 location

Abbott DBS Post-Market Study of Outcomes for Indications Ove...

Movement Disorders

Actively Recruiting

48 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here